Vertex Pharmaceuticals unveiled impressive long-term results for its CRISPR/Cas9 gene therapy, PrCASGEVY, at the EHA Congress ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Janus Henderson Investors, an investment management company, released its “Janus Henderson Venture Fund” first quarter 2025 ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C.

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

These are the world's most influential businesses of the year How Ryan Reynolds Rewrote the Script for Celebrity ...

This study introduces a valuable spring-bead model for epithelial cell layers, designed to improve previous cell-resolved approaches and to understand the connection between the biophysics of ...

Researchers from the Institute of Modern Physics (IMP) of the Chinese Academy of Sciences (CAS), together with collaborators from the Instituto Tecnológico de Aeronáutica in Brazil and Iowa State ...

Abstract We review our recent results on computation of the higher genus characters for vertex operator superalgebras modules. The vertex operator formal parameters are associated to local parameters ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.